Fig 1.
Study outline.
Table 1.
Baseline characteristics.
Table 2.
Distribution of anti-Xa levels.
Table 3.
Distribution of anti-Xa levels stratified for dalteparin and nadroparin.
Table 4.
Anti-Xa levels and bleeding, thrombosis and mortality within three months.
Table 5.
Anti-Xa levels and bleeding, thrombosis and mortality within one month.